MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement
2024年11月7日 - 10:47PM
ビジネスワイヤ（英語）
MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”,
the “Company”), a clinical-stage biopharmaceutical company
developing targeted immunotherapies for cancer, today announced
that independent director Stan V. Smith, Ph.D. made an individual
purchase of 100,000 shares of MAIA’s common stock, and warrants to
purchase 100,000 shares, of MAIA’s common stock for an aggregate
purchase price of $225,900 as part of the Company’s recent private
placement of common stock and warrants announced by the Company on
October 28, 2024, and which closed on November 1, 2024.
“As one of our original investors, Stan has participated in
nearly every private placement financing round since our Company’s
inception. We are grateful for his consistent participation in our
financings and for his long-time service on our Board,” said Vlad
Vitoc, M.D., Chairman and CEO of MAIA.
Stan Smith, Ph.D. commented, “As a private investor in MAIA, I
believe the science behind the THIO franchise, coupling telomere
targeting and immunogenicity, can be disruptive in the treatment
markets for multiple difficult-to-treat cancer types.”
Dr. Smith is president of Smith Economics Group, Ltd. in
Chicago, providing economic and financial consulting nationwide.
Trained at the University of Chicago and specializing in litigation
economics, Dr. Smith co-authored the first textbook on the subject
of economic damages. Dr. Smith has served as an adjunct professor
at the University of Chicago and at DePaul University College of
Law where he created the first course in the United States in
forensic economics.
Additional details on the private placement can be found in the
Company’s Current Report on Form 8-K filed with the Securities and
Exchange Commission on October 29, 2024, at www.sec.gov.
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on
the development and commercialization of potential first-in-class
drugs with novel mechanisms of action that are intended to
meaningfully improve and extend the lives of people with cancer.
Our lead program is THIO, a potential first-in-class cancer
telomere targeting agent in clinical development for the treatment
of NSCLC patients with telomerase-positive cancer cells. For more
information, please visit www.maiabiotech.com.
Forward Looking Statements
MAIA cautions that all statements, other than statements of
historical facts contained in this press release, are
forward-looking statements. Forward-looking statements are subject
to known and unknown risks, uncertainties, and other factors that
may cause our or our industry’s actual results, levels or activity,
performance or achievements to be materially different from those
anticipated by such statements. The use of words such as “may,”
“might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,”
“believe,” “estimate,” “project,” “intend,” “future,” “potential,”
or “continue,” and other similar expressions are intended to
identify forward looking statements. However, the absence of these
words does not mean that statements are not forward-looking. For
example, all statements we make regarding (i) the initiation,
timing, cost, progress and results of our preclinical and clinical
studies and our research and development programs, (ii) our ability
to advance product candidates into, and successfully complete,
clinical studies, (iii) the timing or likelihood of regulatory
filings and approvals, (iv) our ability to develop, manufacture and
commercialize our product candidates and to improve the
manufacturing process, (v) the rate and degree of market acceptance
of our product candidates, (vi) the size and growth potential of
the markets for our product candidates and our ability to serve
those markets, and (vii) our expectations regarding our ability to
obtain and maintain intellectual property protection for our
product candidates, are forward looking. All forward-looking
statements are based on current estimates, assumptions and
expectations by our management that, although we believe to be
reasonable, are inherently uncertain. Any forward-looking statement
expressing an expectation or belief as to future events is
expressed in good faith and believed to be reasonable at the time
such forward-looking statement is made. However, these statements
are not guarantees of future events and are subject to risks and
uncertainties and other factors beyond our control that may cause
actual results to differ materially from those expressed in any
forward-looking statement. Any forward-looking statement speaks
only as of the date on which it was made. We undertake no
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise, except as required by law. In this release, unless the
context requires otherwise, “MAIA,” “Company,” “we,” “our,” and
“us” refers to MAIA Biotechnology, Inc. and its subsidiaries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241107224556/en/
Investor Relations Contact +1 (872) 270-3518
ir@maiabiotech.com
Maia Biotechnology (AMEX:MAIA)
過去 株価チャート
から 10 2024 まで 11 2024
Maia Biotechnology (AMEX:MAIA)
過去 株価チャート
から 11 2023 まで 11 2024
